WO2013058594A2 - 항염 활성을 갖는 발효녹용 추출물의 제조 방법, 이로부터 얻어진 추출물 및 이러한 추출물의 용도 - Google Patents

항염 활성을 갖는 발효녹용 추출물의 제조 방법, 이로부터 얻어진 추출물 및 이러한 추출물의 용도 Download PDF

Info

Publication number
WO2013058594A2
WO2013058594A2 PCT/KR2012/008588 KR2012008588W WO2013058594A2 WO 2013058594 A2 WO2013058594 A2 WO 2013058594A2 KR 2012008588 W KR2012008588 W KR 2012008588W WO 2013058594 A2 WO2013058594 A2 WO 2013058594A2
Authority
WO
WIPO (PCT)
Prior art keywords
antler
extract
complex
fermentation extract
aspergillus
Prior art date
Application number
PCT/KR2012/008588
Other languages
English (en)
French (fr)
Korean (ko)
Other versions
WO2013058594A3 (ko
Inventor
정창휘
최학주
김동희
Original Assignee
(주)메레데코리아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)메레데코리아 filed Critical (주)메레데코리아
Priority to CN201280058853.XA priority Critical patent/CN104105492B/zh
Publication of WO2013058594A2 publication Critical patent/WO2013058594A2/ko
Publication of WO2013058594A3 publication Critical patent/WO2013058594A3/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment

Definitions

  • the present invention relates to a method for preparing an antler extract, an extract obtained therefrom and the use of such an extract, and more particularly to a method for producing an antler extract using fermented extract, an extract obtained therefrom and the use of such an extract.
  • Deer antler usually refers to the horns of a deer. Specifically, it refers to a male's horn that is slightly soft and covered with hairs. In the fall, the horns that have been softened are keratinized, which is for the fight to occupy females during the estrus, and these keratinized horns are less effective than antlers. This greenery misses the harvest time, becomes calcium, hardens, and then falls on its own.
  • antler As a method of taking antler used in traditional Chinese medicine, antler is mixed with various kinds of herbal medicines, pulverized, heated and extracted with water as a solvent to take the filtrate, and the herbal medicines are pulverized and powdered. ( ⁇ ) How to take is mainly used.
  • the above two methods have advantages and disadvantages.
  • the extraction and taking are easy to absorb the active ingredient of the antler, while the active ingredient contained in the extract is discarded.
  • the antler extract is concentrated and used, there is a problem in that the gelation occurs when the solid content is 20% or more.
  • a pill type there is an advantage of taking antler itself, but there is a problem that it is difficult to completely absorb the active ingredient in the body.
  • Korean Laid-Open Patent Publication No. 10-2003-0073134 describes a method of extracting antler which is powdered by adding water to fine antler, heating and extracting it under reduced pressure, and then concentrating and spray-drying the filtrate.
  • the extraction solution is powdered to improve the extraction method and ease of taking, the conventional problem is that a significant amount of the active ingredient contained in the extraction foil is not used and is discarded.
  • Korean Laid-Open Patent Publication No. 10-2005-0090041 describes a method of extracting antler, which is followed by hot water extraction, proteolytic enzyme treatment, and hydrochloric acid decomposition after pulverizing antler or rust.
  • the process proceeds to several stages, which is complicated and time-consuming, and there is a problem in that the use of strong acid destroys the bioactive substances useful for the human body.
  • the conventional antler extract thus obtained has an unpleasant odor and color and is difficult to apply to foods and cosmetics, and only a very small amount is used as a raw material.
  • the present invention is to solve the problems of the conventional antler extraction method, in the present invention, by using only two fermentation methods at low temperature so as not to destroy the physiologically active substance unique to antler, inducing a smooth extraction sufficient short-term decomposition It is an object to provide a method for producing a antler fermentation extract having a high content of the active ingredient to be made.
  • the present invention aims to provide an extract and a complex obtained according to the production method of the present invention.
  • the present invention in order to increase the stability of the antler fermented extract obtained in this way by using a molecular encapsulation technology, designed in a stable formulation to light, air, heat, acid and functional health foods and cosmetics that can maintain anti-inflammatory activity even during the shelf life
  • the purpose is to provide.
  • step 1 Adding purified water to the sliced antler, followed by hot water extraction and filtration (step 1);
  • step 2 Adding a Bacillus strain culture solution to the liquid powder obtained in step 1 and fermenting to obtain a first fermentation extract (step 2); And
  • step 3 After adding purified water to the antler obtained in step 1, aspergillus strain culture solution is added and fermented to obtain a second fermentation extract (step 3). .
  • stirring and molecular encapsulation After adding a clathrate complex to at least one selected from the group consisting of the first fermentation extract, the second fermentation extract, and a mixture of the first fermentation extract and the second fermentation extract, stirring and molecular encapsulation It is preferable to further include.
  • step 1 200 to 500 parts by weight of purified water is added per 100 parts by weight of chopped antler, and hot water extraction is preferably performed at 80 to 100 ° C.
  • step 2 10 to 30 parts by weight of the Bacillus strain culture solution is added per 100 parts by weight of chopped deer antler, fermentation is preferably carried out for 2 to 3 days at 30 to 40 °C.
  • Bacillus strain culture solution contains Bacillus casei.
  • step 3 10 to 30 parts by weight of Aspergillus strain culture solution is added per 100 parts by weight of chopped deer antler, it is preferable that the fermentation is carried out for 2 to 3 days at 50 to 70 °C.
  • the Aspergillus strain culture contains aspergillus casei .
  • At least one selected from the group consisting of a first fermentation extract, a second fermentation extract, and a mixture of the first fermentation extract and the second fermentation extract contains 20 to 30 parts by weight of cyclodextrin per 100 parts by weight of this mixture.
  • the clathrate complex is selected from cyclodextrins, crown ethers, polyoxyalkylenes, proporines, polysiloxanes, popazenes, zeolites.
  • the present invention also provides a complex formed from the fermentation extract and the inclusion complex obtained by adding and fermenting a Bacillus strain culture medium to the liquid powder obtained by hot water extraction of the cut antler.
  • the present invention also provides a complex formed from the fermentation extract and the inclusion complex obtained by adding and fermenting the Aspergillus strain culture solution to the solid antler obtained by hot water extraction of the cut antler.
  • the present invention is added to the fermentation broth obtained by adding and fermenting Bacillus strain culture liquid to the liquid powder obtained by hot water extraction of the sliced antler, and the Aspergillus strain culture solution to the solid antler obtained by hot water extraction of the sliced antler; A mixture of fermentation extracts obtained by fermentation and a complex formed from the inclusion complexes are provided.
  • the clathrate complex is selected from cyclodextrins, crown ethers, polyoxyalkylenes, proporines, polysiloxanes, popazenes, zeolites.
  • the present invention also provides a liquid antler fermentation extract of liquid form obtained by autoclaving the product prepared according to the production method of the present invention, or the complex of the present invention.
  • the present invention also provides a powdered antler fermentation extract obtained by autoclaving and lyophilizing the product prepared according to the production method of the present invention, or the complex of the present invention.
  • the present invention is a functional health food containing at least one selected from the antler fermentation extract prepared according to the production method of the present invention, the complex of the present invention, and liquid and powdered antler fermentation extract as an active ingredient, and Provide functional cosmetics.
  • the present invention can solve the problem of the destruction of physiologically active substances by conventional hydrothermal extraction, strong acid, hydrolysis using enzyme by extracting enough active ingredient of antler in a short time by fermentation extraction method using Bacillus and Aspergillus strain only. In addition, it is possible to obtain a high stability of the antler fermentation extract with a high content of a bioactive substance by the molecular encapsulation method.
  • 1 is a photograph showing the molecular weight size of the antler according to fermentation time.
  • Figure 2 is a graph showing the thermal stability test of the gangliosides for each extraction method.
  • 3 is a graph illustrating acid stability tests of gangliosides according to extraction methods.
  • Figure 4 is a graph showing the effect of fermented antler molecular capsules on IL-6 production in serum after simultaneous LPS treatment.
  • 5 is a graph showing the effect of fermented antler molecular capsules on MCP-1 production in serum after simultaneous LPS treatment.
  • FIG. 6 is a graph showing the effect of fermented antler molecular capsules on IL-1b production in serum after simultaneous LPS treatment.
  • FIG. 7 is a graph showing the effect of fermented antler molecular capsules on TNF-a production in serum after simultaneous LPS treatment.
  • a first aspect of the present invention provides a method for producing a antler fermentation extract from antler. More specifically, the present invention comprises the steps of adding purified water to the fine antler and hot water extraction and filtration (step 1); Adding a Bacillus strain culture solution to the liquid powder obtained in step 1 and fermenting to obtain a first fermentation extract (step 2); And adding purified water to the antler obtained in step 1, followed by adding and fermenting the Aspergillus strain culture medium to obtain a second fermentation extract (step 3). do.
  • step 1 purified water is added to the sliced antler, followed by hot water extraction and filtration. More specifically, 200 to 500 parts by weight of purified water is added and more preferably 300 to 40 parts by weight based on 100 parts by weight of dried and shredded antler. This mixed solution is extracted at 80 ° C to 100 ° C for 2 to 5 hours and filtered. If the amount of purified water is less or more than the range described above, the extraction efficiency may be lowered or diluted, which may cause economic problems in subsequent fermentation steps.
  • the obtained product is divided into a liquid component and an antler component.
  • the antler component means solids other than the liquid component of the material obtained by hot water extraction, which means a solid component which contains a lot of keratin and is not dissolved as water.
  • step 2 the Bacillus strain culture solution is added to the liquid powder obtained in the above step and fermented to obtain a first fermentation extract. More particularly, in this step, 10 to 30 parts by weight of Bacillus strain culture medium, preferably 20 to 25 parts by weight, and 30 ° C. to 40 ° C., preferably 35 ° C., per 100 parts by weight of finely divided antler in the liquid powder obtained in the step. Fermentation is carried out for 2 to 3 days at -37 °C.
  • Bacillus strain culture medium is used, and the fermentation strains contained therein include Bacillus casei (Accession No. KACC 91310P ), B. subtilis , B. natto , B. natto , and Bacillus. B. brevis is appropriate.
  • Bacillus strain culture of the present invention is proteus peptone no. 3 310.0g, beef extract 10.0g, yeast extract 5.0g, dextrose 20.0g, polysorbate 80 1.0g, ammonium citrate 2.0g, sodium acetate 5.0g, magnesium sulfate 0.1g, manganese sulfate 0.05g, dipotassium phosphate
  • the solution was incubated overnight by inoculating 20 g of Lactobacillus casei (KACC 91310P).
  • the fermentation temperature is lower or higher than the above-described temperature range, the fermentation does not proceed or the strain loses activity so that the fermentation does not proceed.
  • filtration may be performed to remove unreacted solids.
  • Filtration is preferably performed at least once using a 0.1-3 ⁇ m filter. If the pore size of the filter is less than 0.1 ⁇ m, the filter is very precise and extremely expensive (ultrafiltration method), so there is a problem of low economic efficiency. If the pore size exceeds 3 ⁇ m, there is no bactericidal power and fungi or bacteria are included in the final extract and contaminated during distribution. There is a problem that is likely to be.
  • the first fermentation extract is obtained through the first fermentation extraction step of this step.
  • step 3 10-30 parts by weight, preferably 20-25 parts by weight of Aspergillus strain culture medium is added to the antler obtained in step 1, and then 50 ° C to 70 ° C, preferably 60 ° C to 65 ° C. Fermentation is carried out for 2 to 3 days at °C. Fermentation of antler buckwheat has many keratin components, so it is appropriate to ferment at a high temperature because perfect fermentation does not proceed at relatively low fermentation temperature conditions.
  • Aspergillus strain culture solution is used in this fermentation step, and the fermented strains contained therein are aspergillus casei , aspergillus ducki ( A. oryzae ), and aspergillus niger ( A. niger). ), A. glaucus , and aspergillus niger , among others.
  • the Aspergillus strain culture solution of the present invention can be prepared as follows: Aspergillus Niger KK2 strain 0.1 %% after incubating for 7 days at 28 °C by inoculating in a potato (potato dextrose agar) slope medium Spores were suspended by the addition of Tween 80 solution. 10 mL of the spore suspension (3.5 ⁇ 10 7 spores per 1.0 mL) was inoculated into a 250 mL Erlenmeyer flask containing 90 mL of malt extract and incubated for 48 hours at 200 rpm in a shaker at 28 ° C. seed culture).
  • a 250 mL Erlenmeyer flask containing 47.5 mL of the culture medium was sterilized at 121 ° C. and 1.5 atm for 20 minutes and then seeded. 2.5 mL of the inoculation was incubated for 5 days at 200 rpm in a shaker at 28 °C.
  • the culture medium contains 2.5% rice straw (0.3 mm or less), 1.25% wheat bran (0.4 mm or less), 4.5% corn steep liquor, 0.125% industrial seed yeast It consisted of industrial yeast extract, 0.65% potassium monobasic phosphate, 0.05% copper sulfate pentahydrate, 0.01% cobalt sulfate heptahydrate, and pH was adjusted to 7.0 with 5N sodium hydroxide.
  • filtration may be performed to remove unreacted solids.
  • Filtration is preferably performed at least once using a 0.1-3 ⁇ m filter. If the pore size of the filter is less than 0.1 ⁇ m, the filter is very precise and extremely expensive (ultrafiltration method), so there is a problem of low economic efficiency. If the pore size exceeds 3 ⁇ m, there is no bactericidal power and fungi or bacteria are included in the final extract and contaminated during distribution. There is a problem that is likely to be.
  • the method of the present invention further comprises adding a clathrate complex to the mixture of the first fermentation extract and / or the second fermentation extract, followed by stirring to obtain molecular encapsulation, in order to obtain the antler fermentation extract with increased stability of the present invention.
  • a clathrate complex to the mixture of the first fermentation extract and / or the second fermentation extract, followed by stirring to obtain molecular encapsulation, in order to obtain the antler fermentation extract with increased stability of the present invention. It includes. More specifically, 20 to 30 parts by weight of cyclodextrin is added to 100 parts by weight of the mixed solution of the first fermentation extract and / or the second fermentation extract and stirred at 60 ° C. to 70 ° C. for 4 hours to encapsulate the bioactive substance. In order to more stabilize its molecular capsule, it is cooled slowly to room temperature to prepare a highly stable capsule.
  • the inclusion complex is preferably cyclodextrin, crown ether, polyoxyalkylene, proporine, polysiloxane, popazene, or zeolite, with cyclodextrin being more preferred.
  • the extract or complex of the present invention prepared as described above includes a liquid obtained by performing autoclaving and a powder product lyophilized thereof.
  • autoclaving is carried out at 121 ° C. for 30 minutes.
  • the fermentation extract obtained in the present invention is extracted by two fermentation methods at low temperature, biodegradable substances are not destroyed, and the antler component contained in the extract has many advantages over the extract obtained by the conventional extraction method, and also the molecular encapsulation.
  • By increasing the stability by having the advantage of designing a stable formulation to light, air, heat, acid bar can be used as an active ingredient in functional health food and cosmetics.
  • the rusted mollusk separated in the above (1) was added to 60 kg of purified water, and 1 kg of aspergillus niger culture solution was added thereto, followed by 2 at 60 ° C. Fermentation was daily. Thereafter, filtration was performed using a 1 ⁇ m filter to remove unreacted solids.
  • the composition thus prepared was lyophilized and powdered.
  • the obtained lyophilized powder was able to obtain more than 33kg.
  • 1 kg of dried antler was crushed using a crusher. 1 kg of crushed antler powder was added to 5 L of distilled water, and extracted at 100 ° C. for 7 hours and filtered. At this time, the primary filtration was performed by a 2 ⁇ m filter, the secondary filtration by a 0.45 ⁇ m filter, and the tertiary filtration by a 0.2 ⁇ m filter.
  • Example 1 The total amount of nitrogen of the antler extract finally obtained in Example 1 and Comparative Examples 1 and 2 was analyzed. The results are shown in Table 1 below.
  • the fermented antler molecular capsule according to the present invention can be seen that the total nitrogen and amino acid content is increased several times to several tens of times compared to the antler extract (Comparative Examples 1 and 2) obtained by the conventional method.
  • BSA bovine serum albumin
  • the sample was dissolved in distilled water and the absorbance was measured at 530 nm by carbazole reaction using a UV spectrophotometer, and the content was determined by calculating the content for D-glucuronic acid lactone.
  • Absorbance was measured using a UV spectrophotometer at 530 nm by carbazole reaction using NZP chondroitin sulfate as a standard.
  • the sample was dissolved in distilled water and the absorbance was measured using a UV spectrophotometer at 530 nm by carbazole reaction, and the content was determined by calculating the content for NZP chondroitin sulfate.
  • the absorbance was measured at 549 nm using a Warren method using a UV spectrophotometer, and the content was determined by calculating the content for N-acetylneuraminic acid.
  • Chondroitinase ABC (C2905, Sigma) from Proteus vulgaris was dissolved in 50 mM Tris-HCl 60 mM sodium acetate buffer (pH 8.0) to 1 U / ml.
  • NZP CS NZP CS as a standard, the standard and the sample were dissolved at 10 mg / ml, mixed with a buffer, 30 mU of enzyme, and reacted at 37 ° C. for 12 hours to analyze the content of chondroitin sulfate.
  • EGF-specific ELISA For the analysis of EGF, human EGF-specific ELISA was performed on antler hydrothermal extract, hydrolyzate and fermented extract. In order to prepare a standard curve, the concentration range having linearity was selected through linear regression analysis in the range of 250 pg / ml ⁇ 0 pg / ml, and absorbance analysis was performed by applying three samples to the test in this section. From this, the EGF of the sample was analyzed according to the concentration of the standard EGF.
  • a calibration curve was prepared from peak integration values of Rf 0.39 and 0.42 obtained by dissolving the ganglioside standard (Sigma Co.) in methanol, developing by TLC method, and scanning at a wavelength of 550 nm with a zig-zag TLC scanner.
  • each sample was performed in the same manner as in the standard method to quantify the gangliosides of each sample from the peak integration values of Rf 0.39 and 0.42.
  • the hydrothermal extract, hydrolyzed antler extract, and extracted by fermentation and molecular encapsulation can be seen that the bioactive substance contains a large amount.
  • Example 1 Comparative Example 2 and Example 1 were prepared by the fermentation extraction method without the molecular capsules 4 at 80 °C Changes in gangliosides were measured under severe conditions of temperature storage for one week and acidic conditions for four weeks at pH 1. The results are shown in FIGS. 2 and 3.
  • the antler extracted from hot water at a high temperature shows a significant decrease in the content of gangliosides over time, and in the case of fermentation with a relatively low extraction temperature, the ganglioside content is higher than that of hot water extraction, but this also decreases.
  • the ganglioside content of the molecular encapsulated deer antler did not change much as the initial state over time.
  • the antler extracted from hot water at high temperature shows a significant decrease in the content of gangliosides over time in strong acid conditions, and in the case of fermentation with a relatively low extraction temperature, the ganglioside content is higher than that of hot water extraction. It can be seen that the decrease. However, the content of the gangliosides of the antler molecule encapsulated in the molecular weight did not change much like the initial state over time.
  • mice were used in the experiment after adapting the Balb / c mice purchased from the Korea Experimental Animal Center in the laboratory environment for one week.
  • the conditions of the animal kennel were a conventional system, 22 ⁇ 2 ° C., 12 hours of the day were illuminated at 200-300 Lux, and 12 hours were all blocked.
  • Animals were supplied with solid feed (more than 22.1% crude protein, less than 8.0% crude fat, less than 5.0% crude fiber, less than 8.0% crude ash, more than 0.6% calcium, more than 0.4% phosphorus, Samyangsa, no antibiotics) and water.
  • lipopolysaccharide is manufactured by Sigma (Sigma Co., USA), physiological saline is a foreign pharmaceutical product, and IL-1 ⁇ , IL-6, TNF- ⁇ , and MCP-1 ELISA kit Millipore Inc. (USA) was used, and other reagents were used as express reagents.
  • the instrument used in this experiment was centrifuged. (Beckman Co., USA), roller mixing. (Gowon scientific technology Co., Korea), vortex mixer (Vision scientific Co., Korea), Luminex (Millipore, Co., USA) and the like were used.
  • LPS lipopolysaccharide
  • IL-6 was measured in the LPS-induced acute inflammation model after administration of BALB / c mice for 7 days after fermentation antler capsules.
  • fermented antler molecular capsule 100 administration group showed 301.6 ⁇ 56.7 (pg / ml)
  • fermented antler molecular capsule 200 administration group showed 212.2 ⁇ 9.8 (pg / ml), significantly increased compared to normal group.
  • the concentration-dependency was significantly higher than that of the control group. (** p ⁇ 0.01, *** p ⁇ 0.001) decreased.
  • the results are shown in FIG.
  • IL-1b was measured in LPS-induced acute inflammation model after administration of fermented antler molecular capsules to BALB / c mice for 7 days, and 25.6 ⁇ 5.6 (pg / ml) in control group and 116.8 ⁇ in control group 8.6 (pg / ml), 61.2 ⁇ 11.1 (pg / ml) of fermented antler molecular capsule 100 and 51.6 ⁇ 9.2 (pg / ml) of fermented antler molecular capsule 200 were significantly increased compared to normal group. In the fermented deer antler capsule group, the concentration-dependence was significantly higher than that of the control group. (** p ⁇ 0.01, *** p ⁇ 0.001) decreased. The results are shown in FIG.
  • the present invention can extract the antler by the most natural fermentation method and reduce the destruction of physiologically active substances of the antler, increase the content of the active ingredient and also increase the productivity, it is usefully used as a manufacturing method of the antler extract used in various fields Can be.
  • the present invention is suitable for wide use in food, cosmetics, etc. by systematically revealing the anti-inflammatory activity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Medical Informatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
PCT/KR2012/008588 2011-10-20 2012-10-19 항염 활성을 갖는 발효녹용 추출물의 제조 방법, 이로부터 얻어진 추출물 및 이러한 추출물의 용도 WO2013058594A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280058853.XA CN104105492B (zh) 2011-10-20 2012-10-19 具有抗炎活性的发酵鹿茸提取物的制备方法、由此得到的提取物及该提取物的用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110107597A KR101169775B1 (ko) 2011-10-20 2011-10-20 항염 활성을 갖는 발효녹용 추출물의 제조 방법, 이로부터 얻어진 추출물 및 이러한 추출물의 용도
KR10-2011-0107597 2011-10-20

Publications (2)

Publication Number Publication Date
WO2013058594A2 true WO2013058594A2 (ko) 2013-04-25
WO2013058594A3 WO2013058594A3 (ko) 2013-06-20

Family

ID=46717564

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/008588 WO2013058594A2 (ko) 2011-10-20 2012-10-19 항염 활성을 갖는 발효녹용 추출물의 제조 방법, 이로부터 얻어진 추출물 및 이러한 추출물의 용도

Country Status (3)

Country Link
KR (1) KR101169775B1 (zh)
CN (1) CN104105492B (zh)
WO (1) WO2013058594A2 (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101750620B1 (ko) * 2015-09-11 2017-06-27 (주)엠앤씨생명과학 구절초를 이용한 삼투압 효소 발효물의 제조방법, 이로부터 제조된 발효물 및 이를 포함하는 화장료, 식품 또는 약학 조성물
KR101750619B1 (ko) * 2015-09-11 2017-06-27 (주)엠앤씨생명과학 여주와 어성초를 이용한 삼투압 효소 발효물의 제조방법, 이로부터 제조된 발효물 및 이를 포함하는 화장료, 식품 또는 약학 조성물
KR101761006B1 (ko) * 2015-07-29 2017-07-26 (주)엠앤씨생명과학 삼투압 효소 발효방법
CN111812333A (zh) * 2020-06-29 2020-10-23 吉林省东北亚生物科技有限公司 对比鹿筋天然肽和酶解肽抗类风湿性关节炎活性的方法
CN112494518A (zh) * 2020-11-18 2021-03-16 中科健康产业集团股份有限公司 一种鹿茸酒的制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105105130A (zh) * 2015-09-17 2015-12-02 辽阳千山呈龙科技有限公司 一种鹿茸酵素的加工方法
KR101776686B1 (ko) * 2016-08-26 2017-09-08 유창우 높은 강글리오사이드 함량을 지니는 녹용 발효물 고형 제제의 제조 방법
KR102033501B1 (ko) 2019-03-06 2019-11-29 ㈜바이오션 콘드로이친황산 함량이 증가된 녹용 가수분해발효물, 그 제조방법, 및 이를 포함하는 식품
KR102227709B1 (ko) * 2019-04-09 2021-03-12 최학주 면역 증강 기능이 있는 발효 녹용 조성물 및 이의 제조방법
CN110876378A (zh) * 2019-12-11 2020-03-13 利民化学有限责任公司 一种智能微胶囊悬浮剂及其制备方法
KR102441355B1 (ko) 2021-11-11 2022-09-07 주식회사 바이오케어 강글리오사이드 함량이 증대된 녹용 추출물의 제조방법
KR102621766B1 (ko) * 2021-11-26 2024-01-12 한국양토양록축산업협동조합 항노화, 항균 및 항염 활성을 갖는 발효녹용 추출물의 제조방법, 이로부터 얻어진 추출물 및 이러한 추출물의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920003960A (ko) * 1990-08-31 1992-03-27 정형식 안정화된 드링크류의 제조방법
WO2001043548A1 (en) * 1999-12-17 2001-06-21 Agrofresh Inc. Synthesis methods, complexes and delivery methods for the safe and convenient storage, transport and application of compounds for inhibiting the ethylene response in plants
KR100972116B1 (ko) * 2009-10-29 2010-07-23 (주)한국파비스 알엔디 생약 발효물의 제조 방법, 이에 의해 제조된 생약 발효물 및 이를 포함하는 식품
KR20100090514A (ko) * 2009-02-06 2010-08-16 (주)아모레퍼시픽 성장 촉진용 식품 조성물
KR20110106759A (ko) * 2010-03-23 2011-09-29 광동제약 주식회사 바실러스 서브틸리스 ｋｃｔｃ 11454 ｂｐ로 발효시킨 녹용을 유효성분으로 포함하는 면역기능 증강 및 조혈기능 개선용 조성물 및 그 제조방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920003960A (ko) * 1990-08-31 1992-03-27 정형식 안정화된 드링크류의 제조방법
WO2001043548A1 (en) * 1999-12-17 2001-06-21 Agrofresh Inc. Synthesis methods, complexes and delivery methods for the safe and convenient storage, transport and application of compounds for inhibiting the ethylene response in plants
KR20100090514A (ko) * 2009-02-06 2010-08-16 (주)아모레퍼시픽 성장 촉진용 식품 조성물
KR100972116B1 (ko) * 2009-10-29 2010-07-23 (주)한국파비스 알엔디 생약 발효물의 제조 방법, 이에 의해 제조된 생약 발효물 및 이를 포함하는 식품
KR20110106759A (ko) * 2010-03-23 2011-09-29 광동제약 주식회사 바실러스 서브틸리스 ｋｃｔｃ 11454 ｂｐ로 발효시킨 녹용을 유효성분으로 포함하는 면역기능 증강 및 조혈기능 개선용 조성물 및 그 제조방법

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101761006B1 (ko) * 2015-07-29 2017-07-26 (주)엠앤씨생명과학 삼투압 효소 발효방법
KR101750620B1 (ko) * 2015-09-11 2017-06-27 (주)엠앤씨생명과학 구절초를 이용한 삼투압 효소 발효물의 제조방법, 이로부터 제조된 발효물 및 이를 포함하는 화장료, 식품 또는 약학 조성물
KR101750619B1 (ko) * 2015-09-11 2017-06-27 (주)엠앤씨생명과학 여주와 어성초를 이용한 삼투압 효소 발효물의 제조방법, 이로부터 제조된 발효물 및 이를 포함하는 화장료, 식품 또는 약학 조성물
CN111812333A (zh) * 2020-06-29 2020-10-23 吉林省东北亚生物科技有限公司 对比鹿筋天然肽和酶解肽抗类风湿性关节炎活性的方法
CN112494518A (zh) * 2020-11-18 2021-03-16 中科健康产业集团股份有限公司 一种鹿茸酒的制备方法

Also Published As

Publication number Publication date
CN104105492B (zh) 2017-12-05
CN104105492A (zh) 2014-10-15
WO2013058594A3 (ko) 2013-06-20
KR101169775B1 (ko) 2012-07-31

Similar Documents

Publication Publication Date Title
WO2013058594A2 (ko) 항염 활성을 갖는 발효녹용 추출물의 제조 방법, 이로부터 얻어진 추출물 및 이러한 추출물의 용도
WO2017074037A1 (ko) 효소 생산능이 우수한 전통 발효식품 유래 신규 균주 및 이를 이용하여 곡물 발효 효소식품을 제조하는 방법
WO2012060579A2 (ko) 항균용 유산균 사균체 및 이의 제조방법
WO2014193014A1 (ko) 나노형 김치 유산균
KR101373940B1 (ko) 생리활성물질의 양이 증가된 누에고치 발효·효소 가수분해물의 제조 방법, 이로부터 얻어진 가수분해물 및 이러한 가수분해물의 항염 활성 용도
WO2015163694A1 (ko) 마늘 발효 조성물의 제조방법 및 이 방법으로 제조된 마늘 발효 조성물
WO2018186700A1 (ko) 실크 피브로인으로 코팅되어 장내 정착성이 향상된 유산균을 포함하는 조성물
KR101784672B1 (ko) 미생물(담자균류균사) 발효하거나, 추가로 효소처리를 통해 생물전환된 느릅나무 발효물을 포함하는 항알레르기능이 있는 치료용 약학조성물 또는 식품조성물
WO2011059292A2 (ko) 피부세포증식 촉진, 항산화 및 항알러지 효과가 우수한 알로에 베라 새순 농축물 또는 추출물
WO2018139898A1 (ko) 인삼열매 다당체를 포함하는 면역 증강용 조성물
WO2021261975A1 (ko) 식물성 콜라겐 및 식물성 뮤신을 포함하는 식물 추출물 및 이의 제조방법
EP2432891A1 (en) Methods for preparing a fermented ginseng concentrate or powder
WO2017204547A1 (ko) 범용성 바이러스 포획 단백질 및 이의 제조방법
WO2010131783A1 (ko) 알로에 발효물과 이의 제조방법 및 이를 이용한 기능성 식품
WO2021230581A1 (ko) 신규한 아커만시아 뮤시니필라 ak32 균주의 발견 및 장 손상의 예방 또는 치료를 위한 응용
WO2024071736A1 (ko) 스트렙토코커스 피오게네스의 사균체 또는 spea 단백질을 포함하는 알레르기 질환의 예방 또는 치료용 약학적 조성물
WO2024048934A1 (ko) 체지방 감소용 신규 유산균 락티플랜티바실러스 플란타룸 sko-001 및 이의 용도
WO2019083289A1 (ko) 장건강 및 장개선 효능을 가지는 수수 및 팥 발효물 및 이의 제조방법
WO2023014054A1 (ko) 블라우티아 속 균주, 류코노스톡 속 균주 또는 루미노코쿠스 속 균주 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2022124569A1 (ko) 3단계 가공처리에 의한 발효 녹용 추출물의 제조방법
WO2022039514A1 (ko) 락토바실러스 사케이 또는 이로부터 유래된 세포밖 소포체를 유효성분으로 포함하는 뇌질환의 치료용 조성물
WO2013109096A1 (ko) 3,6-안하이드로-l-갈락토오스의 제조방법 및 이의 용도
WO2021071159A1 (ko) 서목태의 효모 발효물을 포함하는 혈당강하, 혈압강하 또는 항산화용 조성물 및 상기 조성물의 제조 방법
WO2021080298A1 (ko) 엔테로코커스 패칼리스를 유효성분으로 함유하는 비만 또는 비만으로부터 유도된 대사증후군의 예방 또는 치료용 조성물
WO2021261929A1 (ko) 신규 락토바실러스 루테리 균주 및 이의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12841098

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12841098

Country of ref document: EP

Kind code of ref document: A2